Inhibition of activator protein-1 by sulforaphane involves interaction with cysteine in the cFos DNA-binding domain: implications for chemoprevention of UVB-induced skin cancer.
Sulforaphane is an isothiocyanate derived from cruciferous vegetables that has been linked to decreased risk of certain cancers. Although the role of sulforaphane in the induction of the transcription factor Nrf2 has been studied extensively, there is also evidence that inhibition of the transcription factor activator protein-1 (AP-1) may contribute to the chemopreventive properties of this compound. In this study, we show for the first time that sulforaphane is effective at reducing the multiplicity and tumor burden of UVB-induced squamous cell carcinoma in a mouse model using cotreatment with the compound and the carcinogen. We also show that sulforaphane pretreatment is able to reduce the activity of AP-1 luciferase in the skin of transgenic mice after UVB. Chromatin immunoprecipitation analysis verified that a main constituent of the AP-1 dimer, cFos, is inhibited from binding to the AP-1 DNA binding site by sulforaphane. Electrophoretic mobility shift assay analysis of nuclear proteins also shows that sulforaphane and diamide, both known to react with cysteine amino acids, are effective at inhibiting AP-1 from binding to its response element. Using truncated recombinant cFos and cJun, we show that mutation of critical cysteines in the DNA-binding domain of these proteins (Cys(154) in cFos and Cys(272) in cJun) results in loss of sensitivity to both sulforaphane and diamide in electrophoretic mobility shift assay analysis. Together, these data indicate that inhibition of AP-1 activity may be an important molecular mechanism in chemoprevention of squamous cell carcinoma by sulforaphane.
Dickinson
Sally E
SE
Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA.
Melton
Tania F
TF
Olson
Erik R
ER
Zhang
Jian
J
Saboda
Kathylynn
K
Bowden
G Timothy
GT
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D001665:Binding Sites; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000517:prevention & control*; D003545:Cysteine; D004195:Disease Models, Animal; D005260:Female; D017879:Isothiocyanates; D051379:Mice; D011485:Protein Binding; D016760:Proto-Oncogene Proteins c-fos / Q000737:chemistry / Q000378:metabolism; D016755:Proto-Oncogene Proteins c-jun / Q000737:chemistry / Q000378:metabolism; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D012878:Skin Neoplasms / Q000378:metabolism / Q000517:prevention & control*; D013454:Sulfoxides; D013861:Thiocyanates / Q000494:pharmacology*; D018808:Transcription Factor AP-1 / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D014466:Ultraviolet Rays
D016588:Anticarcinogenic Agents; D017879:Isothiocyanates; D016760:Proto-Oncogene Proteins c-fos; D016755:Proto-Oncogene Proteins c-jun; D011994:Recombinant Proteins; D013454:Sulfoxides; D013861:Thiocyanates; D018808:Transcription Factor AP-1; C016766:sulforaphane; D003545:Cysteine